Skip to main content

Table 1 Discovery population characteristics per cohort

From: A cross-omics integrative study of metabolic signatures of chronic obstructive pulmonary disease

Study Discovery cohorts Replication cohorts
ERF RS-I-4 RS-E5 RS-III-2 LLDEEP FINRISK97 DILGOM PIVUS
N 609 2777 686 1485 717 6898 4600 854
Age, mean (sd) 49.0 (13.3) 74.8 (6.5) 68.4 (5.7) 62.8 (5.8) 46.0 (14.3) 48.0 (13.1) 52.3 (13.5) 70 (0)
Women, % (n) 55.8 (340) 58.2 (1615) 57.6 (395) 57.8 (859) 56.3 (404) 51.6 (3561) 53.4 (2458) 48.2 (412)
COPD cases, % (n) 10.0 (61) 12.1 (336) 10.3 (71) 9.0 (134) 13.8 (99) 0.6 (43) 0.8 (35) NA
FEV1/FVC, mean (sd), % of all NA 0.73 (0.08), 48.8 0.76 (0.07), 91.3 0.77 (0.07), 91.9 0.77 (0.08), 100 NA NA 0.76 (0.11), 100
BMI, mean (sd) 27.2 (4.85) 27.4 (4.1) 27.8 (4.3) 27.4 (4.5) 25.4 (4.1) 26.6 (4.5) 27.2 (4.8) 27.1 (4.26)
Current smokers, % (n) 43.3 (264) 12.6 (349) 9.5 (65) 13.7 (203) 20.5 (147) 23.9 (1648) 17.6 (810) 10.2 (87)
Ex-smokers, % (n) 30.0 (183) 56.1 (1559) 57.0 (391) 50.2 (746) NA 22.9 (1577) 26.3 (1210) 41.5 (354)
Never smokers, % (n) 26.6 (162) 31.3 (869) 33.5 (230) 36.1 (536) 79.4 (570) 53.2 (3673) 56.1 (2580) 48.2 (412)
Pack-years of smoking, mean (sd), % of alla 24.9(20.4) 72.7 24.2 (23.4), 64.7 22.0 (20.8) 66.3 19.5 (20.3) 63.8 NA NA NA NA
LLM users, % (n) 12.3 (75) 22.4 (621) 32.5 (223) 22.2 (329) 3.9 (28) 3.4 (237) 15.7 (721) 16.5 (141)
  1. sd standard deviation, RS-E5 consists of RS-I-5, RS-II-3 and RS-III-2; a Pack-years calculated in current and ex-smokers only, so “% of all” excludes never smokers; LLM lipid-lowering medication, NA not applicable